NCT07130500 - Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization | Biotech Hunter

Enrollment

1,000

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2029

Conditions

Schizophrenia DisorderSchizoaffective DisorderBipolar Disorder (BD)Substance Use Disorder (SUD)

Interventions

BEHAVIORAL

Financial incentives for adherence to long-acting injectable medication

This intervention is a randomized controlled trial where patients in the treatment group are offered financial incentives for taking long-acting injectable (LAI) versions of the antipsychotic and substance use disorder medications they need and the control group receives the status quo standard of care.

BEHAVIORAL

Standard of care with monthly surveys

Receives standard outpatient care and incentives for completing monthly surveys.

Trial Locations (5)

15203

Pittsburgh Mercy, Pittsburgh

UPMC Franklin Building, Pittsburgh

15213

UPMC Bellefield Towers, Pittsburgh

UPMC Oxford Building, Pittsburgh

UPMC Western Psychiatric Hospital, Pittsburgh